Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Farmers Insurance
Deloitte
Harvard Business School
Fish and Richardson
Merck
Cipla
Accenture
Daiichi Sankyo
Federal Trade Commission
US Department of Justice

Generated: January 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,601,337

« Back to Dashboard

Summary for Patent: 7,601,337
Title:Delivery of antipsychotics through an inhalation route
Abstract: The present invention relates to the delivery of antipsychotics through an inhalation route. Specifically, it relates to aerosols containing antipsychotics that are used in inhalation therapy. In a method aspect of the present invention, an antipsychotic is delivered to a patient through an inhalation route. The method comprises: a) heating a composition, wherein the composition comprises an antipsychotic, to form a vapor; and, b) allowing the vapor to cool, thereby forming a condensation aerosol comprising particles with less than 5% antipsychotic drug degradation products. In a kit aspect of the present invention, a kit for delivering an antipsychotic through an inhalation route is provided which comprises: a) a thin coating of an antipsychotic composition and b) a device for dispensing said thin coating as a condensation aerosol.
Inventor(s): Rabinowitz; Joshua D (Princeton, NJ), Zaffaroni; Alejandro C (Atherton, CA)
Assignee: Alexza Pharmaceuticals, Inc. (Mountain View, CA)
Application Number:11/488,932
Patent Claim Types:
see list of patent claims
Composition; Delivery; Use;

Drugs Protected by US Patent 7,601,337

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Galen Uk ADASUVE loxapine POWDER;INHALATION 022549-001 Dec 21, 2012 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,601,337

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,048,909 Delivery of beta-blockers through an inhalation route ➤ Subscribe
7,018,621 Delivery of rizatriptan or zolmitriptan through an inhalation route ➤ Subscribe
6,855,310 Delivery of analgesics through an inhalation route ➤ Subscribe
7,488,469 Delivery of caffeine through an inhalation route ➤ Subscribe
7,510,702 Delivery of nonsteroidal antiinflammatory drugs through an inhalation route ➤ Subscribe
6,776,978 Delivery of opioids through an inhalation route ➤ Subscribe
6,797,259 Delivery of muscle relaxants through an inhalation route ➤ Subscribe
7,078,020 Delivery of antipsychotics through an inhalation route ➤ Subscribe
7,442,368 Delivery of stimulants through an inhalation route ➤ Subscribe
7,070,764 Delivery of analgesics through an inhalation route ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,601,337

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 365548 ➤ Subscribe
Austria 401063 ➤ Subscribe
Austria 401064 ➤ Subscribe
Austria 404173 ➤ Subscribe
Austria 404184 ➤ Subscribe
Austria 406878 ➤ Subscribe
Austria 415155 ➤ Subscribe
Austria 418330 ➤ Subscribe
Austria 418971 ➤ Subscribe
Austria 425746 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Fuji
Argus Health
AstraZeneca
Novartis
Fish and Richardson
Daiichi Sankyo
Accenture
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot